The HealthTech 250
An evidence-led shortlist of digital health ventures—built for faster shortlisting, benchmarking, and partner scouting.
Galen Growth’s annual selection of the 250 most promising early-stage Digital Health ventures across the globe. Published annually since 2022, powered by HealthTech Alpha.
Download our Latest 2026 HealthTech 250
All Editions
Browse every HealthTech 250 report published since 2022.
2026
HealthTech 250: The Most Promising Early-Stage Digital Health Ventures of 2026
The latest edition draws from over 55,000 companies and more to 1.5 billion data points. Featuring a 96% cohort survival rate, $1.5–$1.6B raised, 1,001 partnerships, and 3,176 publications across the cohort.
2025
HealthTech 250: The Most Promising Early-Stage Digital Health Ventures of 2025
The 2025 edition draws from over 50,000 digital health companies and close to a billion of structured data points. The cohort demonstrates strong capital efficiency and ecosystem traction, with over $1.5B raised, 700+ partnerships formed, and thousands of peer-reviewed publications and clinical milestones across the selected ventures.
2023
HealthTech 250: The Most Promising Early-Stage Digital Health Ventures of 2023
The 2023 edition evaluated more than 14,000 digital health startups using proprietary analytics across funding, partnerships, scientific output, and commercial momentum. With $896M raised and 100+ partnerships across the selected ventures, the cohort reflects accelerating global expansion, sustained capital deployment, and increasing collaboration between startups and healthcare incumbents.
2022
HealthTech 250: The Most Promising Early-Stage Digital Health Ventures of 2022
The inaugural 2022 HealthTech 250 assessed over 12,500 startups worldwide, leveraging HealthTech Alpha’s data intelligence platform to identify breakout potential. The cohort showcased strong venture backing, expanding partnership networks, and growing scientific validation across the digital health ecosystem.
HealthTech 250 Cohort Statistics by Year
The table below summarizes key cohort metrics across each edition of the HealthTech 250, highlighting the scale of companies evaluated, the depth of structured data analyzed, and the capital and partnership activity within each selected cohort. Together, these figures illustrate the expanding analytical foundation behind the HealthTech 250 and the evolving maturity of early-stage digital health innovation globally.
| Year | Companies Evaluated | Data Points Analyzed | Cohort Funding | Partnerships |
|---|---|---|---|---|
| 2026 | 55,000+ | ~1.5 Billion | $1.5–$1.6B | 1,001 |
| 2025 | 50,000+ | 1.0 Billion | $1.5B+ | 700+ |
| 2023 | 14,000+ | 650 Million+ | $896M | 100+ |
| 2022 | 12,500+ | 250 Million+ | $1.9B | 242 |
HealthTech 250 – Frequently Asked Questions (FAQ)
The HealthTech 250 is an evidence-led annual selection of the most promising early-stage digital health ventures globally. Powered by HealthTech Alpha’s structured data intelligence, companies are assessed using funding momentum, partnership activity, scientific output, and commercial traction signals to identify breakout potential.
